Abstract

Stem cells (SCs) may constitute a perspective alternative to pharmacological treatment in neurodegenerative diseases. Although the safety of SC transplantation has been widely shown, their clinical efficiency in amyotrophic lateral sclerosis (ALS) is still to be proved. It is not only due to a limited number of studies, small treatment groups, and fast but nonlinear disease progression but also due to lack of objective methods able to show subtle clinical changes. Preliminary guidelines for cell therapy have recently been proposed by a group of ALS experts. They combine clinical, neurophysiological, and functional assessment together with monitoring of the cytokine level. Here, we describe a pilot study on transplantation of autologous adipose-derived regenerative cells (ADRC) into the spinal cord of the patients with ALS and monitoring of the results in accordance with the current recommendations. To show early and/or subtle changes within the muscles of interest, a wide range of clinical and functional tests were used and compared in order to choose the most sensitive and optimal set. Additionally, an analysis of transplanted ADRC was provided to develop standards ensuring the derivation and verification of adequate quality of transplanted cells and to correlate ADRC properties with clinical outcome.

Highlights

  • Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by a progressive loss of motor neurons in the central and peripheral nervous system

  • Nine patients presented clinically possible amyotrophic lateral sclerosis (ALS) according to the El Escorial criteria [34], 31 had a disease duration longer than 24 months, and 10 patients were at the advanced disease stage (ALSFRS R < 25)

  • Qualification of ALS patients to controlled pharmacological clinical trials encounters a number of obstacles resulting from the disease character

Read more

Summary

Introduction

Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by a progressive loss of motor neurons in the central and peripheral nervous system. Stem Cells International edaravone, recently registered in Japan and US, relents disease progression in a subgroup of patients without respiratory involvement [2, 3]. Stem cells (SCs) may constitute a perspective alternative to pharmacological treatment in ALS. The safety of SC transplantation has been widely shown [6,7,8], their efficiency in ALS is still unproven. It is due to a limited number of studies, high variability of transplanted cell types, small treatment groups, and fast but nonlinear disease progression and the lack of objective methods able to prove subtle clinical changes

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call